Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes.

Liu J, Hu Y, Zhang H, Xu Y, Wang G

Journal of diabetes and its complications27 Jul 2016Cited by 41 (Europe PMC)

PMID27503404DOI10.1016/j.jdiacomp.2016.07.020PepBankPUB-27503404

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialMechanism
In obese patients with newly diagnosed type 2 diabetes, exenatide increased serum irisin by 19.28 ng/mL compared with baseline.
In plain wordsIn obese patients with diabetes, exenatide increased blood irisin compared with baseline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSerum irisin change
Study
n = 54
Comparator
Baseline
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Irisin increase
19.28 ng/mL
after exenatide
Source sentences
Summary
Exenatide treatment markedly increased serum irisin by 19.28ng/mL (12.59-25.98) compared to baseline (P<0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four obese patients with T2D were treated with exenatide for 12weeks.
Report a problemFND-2750340401
02HumanNon-randomized trialMechanism
In patients with type 2 diabetes after exenatide treatment, increased irisin was linked to decreased fasting blood glucose.
In plain wordsIn patients with diabetes after exenatide treatment, increased irisin was linked to decreased fasting blood sugar.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseIrisin change association with fasting glucose change
Study
n = 54
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Correlation
−0.35 r
irisin and fasting glucose changes
Source sentences
Summary
Increased irisin was significantly correlated with decreased FBG and HbA1c after exenatide treatment (FBG: r=-0.35; HbA1c: r=-0.37; both P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four obese patients with T2D were treated with exenatide for 12weeks.
Report a problemFND-2750340402
03HumanNon-randomized trialMechanism
In patients with type 2 diabetes after exenatide treatment, increased irisin was linked to decreased HbA1c.
In plain wordsIn patients with diabetes after exenatide treatment, increased irisin was linked to decreased HbA1c.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseIrisin change association with HbA1c change
Study
n = 54
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Correlation
−0.37 r
irisin and HbA1c changes
Source sentences
Summary
Increased irisin was significantly correlated with decreased FBG and HbA1c after exenatide treatment (FBG: r=-0.35; HbA1c: r=-0.37; both P<0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-four obese patients with T2D were treated with exenatide for 12weeks.
Report a problemFND-2750340403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.